Sequential treatment with valemetostat and conventional anti‐cancer drugs for refractory aggressive adult T‐cell leukemia/lymphoma: A case report

A 79‐year‐old man presented with respiratory distress associated with a mediastinal mass and pleural effusion, and was diagnosed as having adult T‐cell leukemia/lymphoma. The patient was highly refractory to anticancer drugs and radiotherapy from the time of onset and had progressive respiratory det...

Full description

Saved in:
Bibliographic Details
Published inEJHaem Vol. 5; no. 4; pp. 851 - 854
Main Authors Obama, Kosuke, Yamamoto, Hana, Inoue, Hirosaka
Format Journal Article
LanguageEnglish
Published Hoboken John Wiley & Sons, Inc 01.08.2024
Wiley
Subjects
adult T‐cell leukemia/lymphoma
Antineoplastic drugs
Cancer therapies
case report
Case reports
Chemotherapy
Clinical trials
Conflicts of interest
Drug dosages
epigenetic
Laboratories
Leukemia
Lymphoma
Pleural effusion
Proteins
Radiation therapy
Tumor cells
valemetostat
Online AccessGet full text

Cover

More Information
Summary:A 79‐year‐old man presented with respiratory distress associated with a mediastinal mass and pleural effusion, and was diagnosed as having adult T‐cell leukemia/lymphoma. The patient was highly refractory to anticancer drugs and radiotherapy from the time of onset and had progressive respiratory deterioration. However, his condition became stable with the administration of valemetostat for 11 days, and subsequent low‐dose‐anticancer agents led to a rapid improvement accompanied by high fever and a surge in C‐reactive protein. In this case, the in vivo priming effect of valemetostat on tumor cells may have increased the sensitivity of these cells to conventional anti‐cancer drugs.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.963